<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00192400</url>
  </required_header>
  <id_info>
    <org_study_id>D153-P504</org_study_id>
    <nct_id>NCT00192400</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of One Dose and Two Doses of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A &amp; B, Live Cold-Adapted (CAIV-T) Compared With Placebo in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T
      against culture confirmed influenza illness in healthy children aged at least 6 months and
      less than 36 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date>November 2002</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Educational/Counseling/Training</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint for efficacy is the first episode in the first season in a study child of a culture-confirmed influenza illness, caused by community-acquired subtypes antigenically similar to those contained in the vaccine.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The first episode in the second season in a study child of a culture-confirmed influenza illness, caused by community-acquired subtypes antigenically similar to those contained in the vaccine.</measure>
  </secondary_outcome>
  <enrollment>2160</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAIV-T</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (First Season)

          -  who is aged at least 6 months and less than 36 months of age at the time of
             enrollment;

          -  who is in good health as determined by medical history, physical examination and
             clinical judgement;

          -  whose parent(s)/legal guardian(s) have provided written informed consent after the
             nature of the study has been explained;

          -  who, along with their parent(s)/legal guardian(s), will be available until the
             completion of the first season’s surveillance phase;

          -  whose parent(s)/legal guardian(s), can be reached by study staff for the
             post-vaccination contacts [telephone, clinic or home visit].

        (Second Season)

          -  who was enrolled into the first season of the trial and received at least one
             vaccination in the primary series;

          -  who completed the safety and efficacy evaluations during the first season surveillance
             phase;

          -  who is in good health as determined by medical history, physical examination and
             clinical judgement;

          -  whose parent(s)/legal guardian(s) have provided written informed consent for the
             second season of the trial after the nature of the study has been explained;

          -  who, along with their parent(s)/legal guardian(s), will be available until the
             completion of the second season’s surveillance phase;

          -  whose parent(s)/legal guardian(s), can be reached by study staff for the
             post-vaccination contacts [telephone, clinic or home visit].

        Exclusion Criteria: (First Season)

          -  whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to
             contact for evaluation or study visits during the study period;

          -  with any serious chronic disease (e.g., with signs of cardiac or renal failure or
             severe malnutrition), including progressive neurological disease;

          -  with Down's syndrome or other known cytogenetic disorders;

          -  with a known or suspected disease of the immune system or those receiving
             immunosuppressive therapy, including systemic corticosteroids;

          -  who received any blood products, including immunoglobulin, in the period from six
             months prior to vaccination through to the conclusion of the study;

          -  for whom there is intent to administer any other investigational vaccine or agent from
             one month prior to enrollment through to the conclusion of the study;

          -  have an immunosuppressed or an immunocompromised individual living in the same
             household;

          -  who, at any time prior to entry into this study, received a dose of any influenza
             vaccine (commercial or investigational);

          -  who, in the two weeks prior to entry into this study, received a dose of any influenza
             treatment (commercial or investigational);

          -  with a documented history of hypersensitivity to egg or egg protein or any other
             component of the assigned study vaccine;

          -  with a clinically confirmed respiratory illness with wheezing within two weeks prior
             to enrollment;

          -  who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two
             weeks prior to enrollment or for which use is anticipated during the study;

          -  who were administered any live virus vaccine within one month prior to enrollment or
             expected to receive another live virus vaccine within one month of vaccination in this
             study;

          -  with any medical conditions that in the opinion of the investigator might interfere
             with interpretation of the study results.

        If any of these criteria are met following enrolment, the subject will be excluded from
        subsequent vaccine dosing.

        Note: Pregnancy in a household member or any person who has regular contact with the
        subject is not a contraindication to the enrollment or ongoing participation of the subject
        in the study.

        (Second Season)

          -  whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to
             contact for evaluation or study visits during the study period;

          -  with any serious chronic disease (e.g., with signs of cardiac or renal failure or
             severe malnutrition), including progressive neurological disease;

          -  with Down's syndrome or other known cytogenetic disorders;

          -  with a known or suspected disease of the immune system or those receiving
             immunosuppressive therapy, including systemic corticosteroid of a dose equivalent to 2
             mg/kg/day or greater of prednisolone or equivalent to a total of 20 mg/day or greater
             for children who weigh more than 10 kg, for more than 14 days duration until 2 weeks
             after corticosteroids have been discontinued;

          -  who received any blood products, including immunoglobulin, in the period from six
             months prior to the second season vaccination through to the conclusion of the study;

          -  for whom there is intent to administer any other investigational vaccine or agent from
             one month prior to the second season vaccination through to the conclusion of the
             study;

          -  have an immunosuppressed or an immunocompromised individual living in the same
             household;

          -  who, at any time prior to entry into this study, received a dose of any influenza
             vaccine (commercial or investigational) with the exception of the primary series of
             study vaccine (CAIV-T/placebo);

          -  who, in the two weeks prior to receiving the second season vaccination, received a
             dose of any influenza treatment (commercial or investigational);

          -  with a documented history of hypersensitivity to egg or egg protein or any other
             component of the assigned study vaccine (CAIV-T/placebo);

          -  with a clinically confirmed respiratory illness with wheezing within two weeks prior
             to receiving the second season vaccination;

          -  who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two
             weeks prior to receiving the second season vaccination or for which use is anticipated
             during the study;

          -  who were administered any live virus vaccine within one month prior to receiving the
             second season vaccination or expected to receive another live virus vaccine within one
             month of receiving the second season vaccination;

          -  with any medical conditions that in the opinion of the investigator might interfere
             with interpretation of the study results.

        Note: Pregnancy in a household member or any person who has regular contact with the
        subject is not a contraindication to the enrollment or ongoing participation of the subject
        in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker, MD</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>October 2, 2006</last_update_submitted>
  <last_update_submitted_qc>October 2, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2006</last_update_posted>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

